IP Verse

Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells - EP3377103

The patent EP3377103 was granted to Revitope on Mar 12, 2025. The application was originally filed on Nov 18, 2016 under application number EP16867215A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3377103

REVITOPE
Application Number
EP16867215A
Filing Date
Nov 18, 2016
Status
Patent Maintained As Amended
Feb 7, 2025
Grant Date
Mar 12, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TAKEDA PHARMACEUTICALDec 17, 2021DOLPHINWITHDRAWN
CHERRY BIOLABSDec 16, 2021MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBWITHDRAWN

Patent Citations (27) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2015183875
DESCRIPTIONWO2007062466
DESCRIPTIONWO2013104804
DESCRIPTIONWO2015013671
INTERNATIONAL-SEARCH-REPORTUS2009130106
INTERNATIONAL-SEARCH-REPORTUS2015079093
INTERNATIONAL-SEARCH-REPORTUS2015183875
INTERNATIONAL-SEARCH-REPORTUS2015307564
INTERNATIONAL-SEARCH-REPORTWO2015001361
OPPOSITIONUS2002076406
OPPOSITIONUS2008145362
OPPOSITIONUS2011229476
OPPOSITIONUS2013060010
OPPOSITIONUS2014099254
OPPOSITIONUS2015183875
OPPOSITIONWO2007073499
OPPOSITIONWO2010081173
OPPOSITIONWO2012123755
OPPOSITIONWO2012158818
OPPOSITIONWO2013104804
OPPOSITIONWO2013128194
OPPOSITIONWO2015013671
OPPOSITIONWO2017087789
OPPOSITIONWO2017156178
SEARCHWO2012123755
SEARCHWO2014140358
SEARCHWO2015013671

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Jinming Gu, Jinsong Yang, Qing Chang, Xiaoqing Lu, Jieyi Wang, Mingjiu Chen, Tariq Ghayur, Jijie Gu, "Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-lgâ„¢) Proteins with Unique Activities", PLoS One, (20140513), vol. 9, no. 5, pages 1 - 10, XP055890395-
OPPOSITION- Sherry L. Laporte, Daniel R. Hostetter, Laurie Wong, Jennifer Razo, Linnea Diep, Clayton W. White, Jennifer H. Richardson, W. Michael Kavanaugh, And Bryan A. Irving, "Abstract A203: CD3-EGFR bispecific Probodyâ„¢ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies", Molecular Cancer Therapeutics, (20151201), pages 1 - 4, Molecular Cancer Therapeutics, URL: https://mct.aacrjournals.org/content/14/12_Supplement_2/A203, (20220210), XP055890402-
OPPOSITION- Huang Shuyu; van Duijnhoven Sander M. J.; Sijts Alice J. A. M.; van Elsas Andrea, "Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY., SPRINGER INTERNATIONAL, BERLIN., DE, DE , (19000101), vol. 146, no. 12, doi:10.1007/s00432-020-03404-6, ISSN 0171-5216, pages 3111 - 3122, XP037300178
OPPOSITION- Oran Erster et al, "Site-specific targeting of antibody activitymediated by disease-associated proteases", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20120517), vol. 161, no. 3, doi:10.1016/j.jconrel.2012.05.035, ISSN 0168-3659, pages 804 - 812, XP028409044
OPPOSITION- Langers A M J, Et Al, "MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients", British Journal of Cancer, Nature Publishing Group UK, London, London, (20120401), vol. 106, no. 9, doi:10.1038/bjc.2012.80, ISSN 0007-0920, pages 1495 - 1498, XP055876797
OPPOSITION- M. R. Zaidi, G. Merlino, "The Two Faces of Interferon-gamma in Cancer", Clinical Cancer Research, Association for Cancer Research, US, US, (20111001), vol. 17, no. 19, doi:10.1158/1078-0432.CCR-11-0482, ISSN 1078-0432, pages 6118 - 6124, XP055465827
OPPOSITION- POLU KR et al., "Probody therapeutics for targeting antibodies to diseased tissue", Expert Opin. Biol. Ther., (20140520), vol. 14, no. 8, doi:10.1517/14712598.2014.920814, pages 1049 - 1053, XP055228738
OPPOSITION- Rakash Syed, Et Al, "Role of proteases in cancer: A review", Biotechnology and Molecular Biology Reviews, (20121001), vol. 7, no. 4, doi:10.5897/BMBR11.027, pages 90 - 101, XP055876796
OPPOSITION- CHOI KY et al., "Protease-Activated Drug Development", Therano- stics, (20120208), vol. 2, no. 2, doi:10.7150/thno.4068, pages 156 - 178, XP055263145

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents